Search Press releases Keywords From To 19 May 2019 UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S. Read More 2 May 2019 Transparency notifications BlackRock, Inc. Read More 1 May 2019 UCB and University of Lille anti-tau immunotherapy research highlighted in prestigious international scientific journal ‘Brain’ Read More 25 Apr 2019 UCB's General Meeting of Shareholders Read More 24 Apr 2019 New Data Showcases the Value of CIMZIA® (certolizumab pegol) in Patients with Psoriasis Read More 10 Apr 2019 Transparency notification BlackRock, Inc. Read More Pagination First page Previous page Previous … Page 59 Page 60 Page 61 Page 62 Current page 63 Page 64 Page 65 Page 66 Page 67 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe